valsartan has been researched along with icatibant in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, ME; Komers, R | 1 |
| Endlich, K; Steinhausen, M | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Hulthen, UL; Youssef, S | 1 |
| Ahonen, J; Finckenberg, P; Krogerus, L; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H | 1 |
| Bai, XJ; Qi, ZM; Wang, HX; Zhang, YJ | 1 |
| Brown, NJ; Gebretsadik, T; LeFebvre, J; Murphey, LJ; Petro, JR; Shintani, A | 1 |
| Biggi, A; Cabassi, A; De Iaco, G; Iori, M; Magnani, G; Montanari, A; Musiari, L; Novarini, A; Pelà, GM; Pelloni, I; Pinelli, S | 1 |
| Campbell, DJ; Koid, SS; Ziogas, J | 1 |
2 trial(s) available for valsartan and icatibant
| Article | Year |
|---|---|
Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Bradykinin; Bradykinin B2 Receptor Antagonists; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Female; Heart Rate; Humans; Hypertension; Male; Receptor, Bradykinin B2; Renin; Sodium; Tetrazoles; Valine; Valsartan | 2007 |
Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Bradykinin; Bradykinin B2 Receptor Antagonists; Female; Glomerular Filtration Rate; Humans; Indicators and Reagents; Inulin; Kidney; Male; p-Aminohippuric Acid; Receptor, Bradykinin B2; Renal Circulation; Sodium; Tetrazoles; Valine; Valsartan | 2010 |
6 other study(ies) available for valsartan and icatibant
| Article | Year |
|---|---|
Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Diabetes Mellitus, Experimental; Glomerular Filtration Rate; Hemodynamics; Kinins; Male; Ramipril; Rats; Rats, Sprague-Dawley; Renal Circulation; Tetrazoles; Time Factors; Valine; Valsartan | 1995 |
Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Bradykinin Receptor Antagonists; Drug Synergism; Female; Isoquinolines; Kidney; Kinins; Quinapril; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin-Angiotensin System; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan; Vasodilation | 1997 |
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 1997 |
Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin Receptor Antagonists; Cyclosporine; Dose-Response Relationship, Drug; Drinking; Eating; Electrolytes; Enalapril; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Kallikreins; Kidney; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Renin; Sodium, Dietary; Tetrazoles; Urination; Valine; Valsartan | 2000 |
[Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
Topics: Animals; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Creatine Kinase, MB Form; Disease Models, Animal; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Topics: Amides; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Female; Fumarates; Imidazoles; Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan | 2014 |